NAPHAZOLINE HYDROCHLORIDE
Clinical safety rating
cautionComprehensive clinical and safety monograph for NAPHAZOLINE HYDROCHLORIDE (NAPHAZOLINE HYDROCHLORIDE).
Agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of conjunctival blood vessels and reducing nasal mucosal congestion.
| Metabolism | Not extensively studied; likely hepatic metabolism via unknown enzymes. |
| Excretion | Primarily renal excretion of unchanged drug and metabolites; exact % not established in humans due to limited systemic absorption after topical use. In animal studies, ~30-40% excreted unchanged in urine. |
| Half-life | Approximately 2-3 hours after systemic absorption; clinical effect is limited by local vasoconstriction rather than plasma half-life. |
| Protein binding | Not well characterized; expected to be low (<20%) based on structural analogs. |
| Volume of Distribution | Not established in humans; based on animal data, approximately 0.5-1.0 L/kg, suggesting distribution into total body water. |
| Bioavailability | Ophthalmic and intranasal: low systemic bioavailability due to local vasoconstriction limiting absorption; exact % not determined, estimated <1%. |
| Onset of Action | Ophthalmic: within 10 minutes; Intranasal: within 5-10 minutes. |
| Duration of Action | Ophthalmic: 2-6 hours (shorter with repeated use due to tachyphylaxis); Intranasal: 2-6 hours (rebound congestion with prolonged use). |
| Molecular Weight | 246.73 |
1-2 drops of 0.1% solution in each eye every 3-4 hours as needed; intranasal: 0.05% solution, 1-2 sprays per nostril every 6-8 hours.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required; primarily locally acting with minimal systemic absorption. |
| Liver impairment | No dose adjustment required; use caution in severe hepatic impairment due to potential for systemic effects. |
| Pediatric use | Children ≥6 years: 1-2 drops of 0.1% ophthalmic solution every 6-8 hours; nasal spray 0.05% for children ≥6 years, 1 spray per nostril every 8-10 hours. Contraindicated in infants and children <6 years due to risk of CNS depression. |
| Geriatric use | Elderly patients may be more sensitive to adverse effects (e.g., rebound congestion, hypertension); use lowest effective dose and shortest duration. Avoid in patients with cardiovascular disease or glaucoma. |
| 1st trimester | Avoid use due to potential for vasoconstriction and reduced placental perfusion. |
| 2nd trimester | Use only if clearly needed and benefit outweighs risk; monitor for maternal hypertension and fetal distress. |
| 3rd trimester | Avoid near term; may cause uterine vasoconstriction and fetal hypoxia. |
Clinical note
Comprehensive clinical and safety monograph for NAPHAZOLINE HYDROCHLORIDE (NAPHAZOLINE HYDROCHLORIDE).
| Placental transfer | Limited data; due to low molecular weight, transfer is possible but topical use minimizes systemic exposure. Vasoconstrictive effects may indirectly affect placental perfusion. |
| Breastfeeding | Systemic absorption is minimal after topical use; however, concentrate on nasal mucosa may be absorbed. Avoid application to breast area. Use with caution, monitoring infant for sedation and hypotension. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Naphazoline hydrochloride is an alpha-adrenergic agonist used as a topical decongestant. Systemic absorption is minimal with topical ocular or nasal use; however, theoretical risks include vasoconstriction and reduced uterine blood flow. No adequate and well-controlled studies in pregnant women. Animal studies have not been reported. First trimester: No known teratogenic effects. Second and third trimesters: Potential risk of reduced uteroplacental perfusion when used systemically; topical use at recommended doses unlikely to cause significant effects. Overall, classified as FDA Pregnancy Category C. Caution is advised. |
| Fetal Monitoring | No specific clinical monitoring required for topical use at recommended doses. Monitor for maternal hypertension, tachycardia, or other systemic effects with excessive use. Fetal monitoring only if signs of maternal toxicity or reduced uterine perfusion are suspected. |
| Fertility Effects | No known effects on fertility in humans. Animal reproductive studies have not been conducted. Minimal systemic absorption suggests unlikely impact on reproductive function at recommended topical doses. |
■ FDA Black Box Warning
None
| Serious Effects |
Narrow-angle glaucomaHypersensitivity to naphazoline or any componentConcomitant use with MAO inhibitors or within 14 days of stoppingSevere hypertensionCoronary artery disease
| Precautions | Prolonged use may cause rebound congestion (rhinitis medicamentosa). Use with caution in patients with cardiovascular disease (hypertension, arrhythmias), hyperthyroidism, diabetes, or prostatic hyperplasia. Avoid use in patients with narrow-angle glaucoma. Do not exceed recommended dosage or duration. |
| Food/Dietary | No significant food interactions; avoid excessive caffeine or other stimulants as they may potentiate sympathomimetic effects. |
| Clinical Pearls | Naphazoline is a direct-acting sympathomimetic with rapid onset; use limited to 3-5 days to avoid rebound congestion and rhinitis medicamentosa. Contraindicated in narrow-angle glaucoma due to potential mydriasis. Caution in cardiovascular disease, hypertension, and hyperthyroidism; may elevate BP and cause palpitations. Not for use in infants or children under 6 years due to risk of CNS depression. |
| Patient Advice | Do not use for more than 3-5 consecutive days to avoid worsening congestion and dependence. · Avoid contact with eyes; if eye contact occurs, flush with water for 15 minutes. · Do not share the bottle with others to prevent infection spread. · Store at room temperature, away from light and moisture. · Consult a doctor before use if you have heart disease, high blood pressure, or an enlarged prostate. |
Loading safety data…